Category: Pharma

23andMe, a US-based biotech company, sees its stock plummet to new lows as Sequoia Capital reduces its stake.

by newsworm | Nov 21, 2024 | Pharma | 0 |

23andMe, a US biotech company, has hit new lows as Sequoia Capital, one of its major investors,...

Innocan Pharma Discloses Financial Performance for Third Quarter 2024

by newsworm | Nov 21, 2024 | Pharma | 0 |

Innocan Pharma Corporation, a pharmaceutical technology company, has announced its consolidated...

Lupin Announces FDA Approval of New Edema Treatment in the US Market

by newsworm | Nov 21, 2024 | Lupin, Pharma | 0 |

Pharmaceutical company Lupin Limited has launched Bumetanide Injection USP, a generic version of...

Building bridges between our industry and policymakers

by newsworm | Nov 21, 2024 | Pharma | 0 |

A reception was held at the Australian Parliament House, co-hosted by AusBiotech and MTPConnect,...

Introducing Debut’s Game-Changing Biotech Offerings in Professional Beauty Routines

by newsworm | Nov 21, 2024 | Pharma | 0 |

Debut, a biotech beauty company, has announced its entry into the professional beauty services...

Pharma giants hit with lawsuit by Oceanside Unified over exorbitant insulin prices.

by newsworm | Nov 20, 2024 | Pharma | 0 |

The Oceanside Unified School District is suing several pharmaceutical companies, including Eli Lilly, Sanofi, and Novo Nordisk, as well as pharmacy benefits managers, CVS, Cigna, and UnitedHealth, alleging that they engaged in...

Boston Scientific subsidiary Lupin wins FDA approval for generic ADHD treatment.

by newsworm | Nov 20, 2024 | Lupin, Pharma | 0 |

Lupin Inc. has received approval from the US Food and Drug Administration (FDA) to market its generic version of the attention deficit hyperactivity disorder (ADHD) medication Strattera (atomoxetine). The company’s...

Zydus and Natco face potential patent infringement lawsuits from Roche to block generic versions of Evrysdi.

by newsworm | Nov 20, 2024 | Natco, Pharma, Zydus | 0 |

Roche has filed a patent infringement lawsuit against Zydus and Natco, two Indian generic drug makers, to prevent them from launching generic versions of its spinal muscular atrophy (SMA) treatment, Evrysdi. The lawsuit was...